Logo
 
Chat Here
Chat Here
Peer review
paper published
by GAP

Medical writing,
Clinical Expertise,
Technical Development
is our core
competency

Data Safety
Monitoring Board
(DSMB)

DSMB

Clinical
Events
Committee

CEC

Safety
Assessment
Committees

SAC

Message
from
the CEO

President
and
Co-founder

Our
Service
Card

Business
Card

Automated
Remote Data Manage
QC and Medical
Monitoring
Service

Business
Card

We wrote
the book
On
GPV & E

Pharmacovigilance
is
What We Do.

We wrote
the book
On
Immuno-Oncology

Oncology-Clinical
Devlopment
is
What We Do.

javascript


GAP: Peer Review Articles In-Print.


Published Articles by GAP.


1. Efficacy and safety of Specific Conjugate Particle (SCP)- Doxorubicinin Patients with Recurrent High-Grade Gliomas, a Randomized Clinical Study(08-June-2017)


1. Efficacy and safety of Specific Conjugate Particle (SCP)- Doxorubicin in Patients with Soft Tissue Sarcoma, a Randomized Clinical Study(10-April-2017)


2. Randomized clinical study of SCP pacliataxel in patients with advanced cervical cancer(18-February-2017)


3. Propolis gel versus benzydamine in preventing oral mucositis for patients irradiated in head and neck: a preliminary study(17-February-2017)


4. Immunotherapy and urinary bladder cancer(07-February-2017)


5. The histogenesis of Ewing Sarcoma(07-February-2017)


6. Immunotherapy and squamous cell carcinoma(06-February-2017)


7. Immunotherapy and small cell lung cancer (SCLC)(04-February-2017)


8. Social support, quality of life and mental health status in breast cancer patients(01-February-2017)


9. New Targets in Treating Multiple Myeloma(21-December-2016)


10. Immunotherapy and myeliod metaplasia(02-December-2016)


11. Immunotherapy and Acute Lymphoblastic Leukemia(3-November-2016)


12. Immunotherapy and Ovarian Cancer(27-October-2016)


13. Immunotherapy and Gastric Cancer(21-October-2016)


14. Immunotherapy and Uterine Cancer(22-September-2016)


15. Immunotherapy for cancers of the biliary tract(25-August-2016)


16. Immunotherapy in basal cell carcinoma(22-August-2016)


17. Immunotherapy and target therapy in non-Hodgkin's lymphoma(25-June-2016)


18. Application of molecular targeted therapy for refractory metastatic thyroid cancers(17-June-2016)


19. Immunotherapeutic approach to nasopharyngeal cancer(27-May-2016)


20. Immunotherapeutic Approach to Oropharyngeal Cancer(27-May-2016)


21. Immunotherapeutic Approach to Laryngeal Cancer(25-May-2016)


22. Immunotherapy and polycythemia vera(13-May-2016)


23. Role of Immunotherapy in Post Transplantation Lymphoproliferative Disorders(11-May-2016)


24. Immunotherapy in Hodgkin Lymphoma.(23-April-2016)


25. Immunotherapy and colon cancer(04-April-2016)


26. HIV AND HTLV1 ASSOCIATED LYMPHOMA & IMMUNOTHERAPY(28-March-2016)


27. Immunotherapy and Cervical Cancer(28-March-2016)


28. Therapeutic approach to CML in TKI era(01-March-2016)


29. Immunotherapeutic approach to Anal Cancer.(01-March-2016)


30. Immunotherapeutic approach to Osteosarcoma.(26-Feb-2016)


31. Emerging role of immunotherapy in breast cancer.(26-Feb-2016)


32. Novel approaches in treatment of adult AML(26-Feb-2016)


33. Novel targets and breast cancer treatment.(26-Feb-2016)


34. Therapeutic approach to Chordomas(26-Feb-2016)


35. Targeted therapy for Chondrosarcoma.(25-Feb-2016)


36. New targets in treatment of myelodysplastic syndrome.(06-Feb-2016)


37. Immunotherapeutic Approach to Squamous Cell Carcinoma of the Head and Neck.(03-Feb-2016)


38. Role of immunotherapy for H. pylori in gastric cancer.(09-November-2015)


39. Gastrointestinal events associated with Ipilimumab, Pazopanib, Anti PD-1 antibody and their management: single and combination therapies.(27-October-2015)


40. Cancer-related fatigue and its management. (04-May-2015)


41. COX-2 inhibitors and their role in cancer prevention and treatment.(17-April-2015)


42. Management of neurological adverse events associated with immunotherapy and a possible algorithm for clinical management.(08-April-2015)


43. A Review article on clinical trials on hybrid drugs and nanohybrid technologies in drug development that combat cancer.(10-February-2015)


44. A review article on Neuropathic pain.(04-January-2015)


45. Principles of nutritional support in cancer patients.(28-December-2014)


46. Growth Factor As A Supportive Treatment In Chemotherapy.(22-November-2014)


47. A Review on Role of Peptide Vaccines in Cancer Therapy Treatment of Cancer Disease by Peptide Vaccine.(06-November-2014)


48. A Review Article on Emerging Role of Hybrid Molecules in Treatment of Breast Cancer.(04-November-2014)


49. Mechanisms of Resistance to Rituximab in B-cell Lymphoma(08-October-2014)


50. Complementary medicines and cancer.(28-September-2014)


51. Anti-inflammatory agents and their role in atherosclerosis.(06-August-2014)


52. Immunotherapy in Metastatic Renal Cell Carcinoma.(06-May-2014)


53. Role of Vascular Endothelial Growth Factor Receptor Inhibitors in Refractory Cervical Cancer.(06-April-2014)


54. Safety and Efficacy of Peptide Based Vaccines.(06-March-2014)


55. A review of newer technologies in development of nanomedicines for cancers.(06-February-2014)


56. A Review on Clinicopathological Correlation between Classical Inflammatory Bowel Disease and Immunotherapy Related Inflammatory Bowel Disease.(10-January-2014)


57. Mechanisms of drug resistance in Glioblastoma Multiforme.(06-January-2014)


58. Toxicities Associated with Antibody Drug Conjugates.(06-December-2013)


59. PROTEASOME INHIBITION IN LYMPHOPROLIFERATIVE DISORDER.(17-November-2013)